LCZ696 (sacubitril/valsartan): can we predict who will benefit?

Affiliations

Free article

Editorial

G William Dec. J Am Coll Cardiol. 2015.

Free article

. 2015 Nov 10;66(19):2072-2074.

doi: 10.1016/j.jacc.2015.08.877.

¹ Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: gdec@partners.org.

No abstract available

Keywords: neprilysn inhibition; sacubitril/valsartan.

Comment on

Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.
Simpson J, Jhund PS, Silva Cardoso J, Martinez F, Mosterd A, Ramires F, Rizkala AR, Senni M, Squire I, Gong J, Lefkowitz MP, Shi VC, Desai AS, Rouleau JL, Swedberg K, Zile MR, McMurray JJV, Packer M, Solomon SD; PARADIGM-HF Investigators and Committees. Simpson J, et al. J Am Coll Cardiol. 2015 Nov 10;66(19):2059-2071. doi: 10.1016/j.jacc.2015.08.878. J Am Coll Cardiol. 2015. PMID: 26541915 Clinical Trial.